24/04/08 - Preliminary Results for year-ended 31 December 2007

Cyprotex reports its preliminary results for the year ended 31 December 2007

23/04/08 - Cyprotex Launches New Catalogue

Cyprotex launches its new catalogue for experimental and predictive ADME and PK services

21/04/08 - Notification of Preliminary results for year-ended 31 December 2007

Cyprotex reports notification of its preliminary results for the year-ended 31 December 2007

02/04/2008 - Cyprotex introduces a new product line - Cloe® Select

Cyprotex introduces new product line Cloe® Select - a portfolio of bespoke ADME and PK services.

20/03/2008 - Appointment of New Chairman

Cyprotex announces a New Chairman effective from 1st April 2008.

25/02/2008 - Cyprotex working with NIH

Cyprotex starts working with the NIH Chemical Genomics Centre.

17/12/2007 - Trading Update: Progress in line with Expectations

Cyprotex announces a trading update for 2007.

29/11/07 - Thermodynamic Solubility Assessment Service Announced

Cyprotex announces that it has extended its portfolio of Cloe® Screen services to include an assessment of thermodynamic solubility.

28/11/07 - Notification of Director Shareholder Dealing

Director share purchases

23/11/07 - Notification of Director Shareholder Dealing

Director share purchases

12/10/07 - Trading Update : Building Confidence

The Director’s confidence with Cyprotex’s core operations continued to build during the third quarter of 2007. The Group enters the final three months of its year on an optimistic note.

09/10/07 - Notification of Director Shareholder Dealing

Director share purchases

30/08/07 - Interim results for the six months to 30 June

Cyprotex today reports its Interim Results for the half year ended 30 June 2007.

14/08/07 - Share Allotment

Progress in line with expectations.

31/07/07 - Trading Update

Progress in line with expectations.

17/07/07 - Cyprotex provides in silico PK prediction for EU-funded project ‘OSIRIS’ to address REACH legislation

Cyprotex is providing PK prediction capability to the EU-funded OSIRIS (Optimized Strategies for Risk Assessment of Chemicals based on Intelligent Testing) consortium.

07/06/07 - Cyprotex Launches New Cloe® Screen Assay to Improve the Prediction of in vivo Pharmacokinetics

Cyprotex announces the development of Cloe Screen® microsomal binding assay.

06/06/07 - AGM Statement

Cyprotex today announces the outcome of its Annual General Meeting.

02/04/07 - Results of Extraordinary General Meeting of 2 April 2007

Earlier today Cyprotex held an EGM to consider the resolutions contained in the notice to shareholders dated 6 March 2007.

29/03/07 - Preliminary results for year ended 31 December 2006

Cyprotex reports its preliminary results for the year ended 31 December 2006.

29/03/07 - Cyprotex Extends Cloe® Screen Mechanism-Based Inhibition Service

Cyprotex announces that it has enhanced its Cloe® Screen Mechanism-Based Inhibition service to include 4 additional cytochrome P450 isoforms.

23/03/07 - Requisitioned Extraordinary General Meeting

14/03/07 - Change in the date of the Preliminary Results announcement to 29 March 2007

16/02/07 - Solid progress during 2006

Cyprotex PLC confirms the release date for its 2006 preliminary results.

13/02/07 - Requisition of Extraordinary General Meeting

Cyprotex PLC received a requisition on 12 February for an EGM.

15/12/06 - Total Voting Rights and Share Capital

06/12/06 - Cyprotex announces a trading update for 2006

Cyprotex today announces a trading update for 2006.

20/11/06 - Robert Atwater Profile in the Daily Telegraph

17/11/06 - Cyprotex announces issue of shares

Cyprotex announces the issue of new ordinary shares

16/11/06 - Directors Dealings

Statement of Director Sharedealings

24/10/06 - Cyprotex launches new screening service

Cyprotex adds MDR1-MDCK permeability screening service to the Cloe® Screen range of in vitro ADMET assays

30/08/06 - Interim results for the six months to 30 June

Cyprotex today reports its Interim Results for the half year ended 30 June 2006.

21/08/06 - Cyprotex plc - First Half Results - Wednesday, 30th August 2006

Cyprotex is due to announce its Interim Results for the six months ended 30th June 2006 on Wednesday, 30th August 2006.

05/07/06 - Cyprotex launches new screening service

Cyprotex annouces the launch of mechanism-based inhibition of cytochrome P450 screening service

28/06/06 - Directors Dealings

Statement of Director share dealing.

28/06/06 - Directors Dealings

Statement of Director share dealing.

06/06/06 - Directors Dealings

Statement of Director share dealing.

01/06/06 - AGM Statement

Cyprotex today announces the outcome of its Annual General Meeting

26/05/06 - Cyprotex expands further in to the United States

Cyprotex appoints Global Head of Business Development

09/05/06 - 'Everything You Wanted to Know About ADME, But Were too Afraid to Ask'

Cyprotex launches guide for the interpretation of in vitro data.

26/04/06 - Directorate changes

Cyprotex appoints Russell Gibbs to the Board as Chief Financial Officer

05/04/06 - Preliminary Results for year ended 31 December 2005

Cyprotex today reports its preliminary results for the year ended 31 December 2005

26/03/06 - Notice of Preliminary Results.

Cyprotex will be announcing its Preliminary Results for the year ended 31 December 2005 on Wednesday 5 April 2006

27/01/06 - Notification of substantial shareholding

Cyprotex today announces that it today received notification that the Bank of Scotland has beneficially acquired 27,115,098 ordinary shares in the Company

11/01/06 - Cyprotex Adds New Service to Support Early Drug Discovery

Cyprotex today announces the launch of a new service to help drug discovery groups to assess new oral drug candidates.

30/12/05 - Cyprotex announces a trading update for 2005

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces a trading update for 2005.

26/10/05 - Cyprotex Receives Dual Boost for Research Development

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, is pleased to announce that it has received peer-approved publication of its "virtual human and rat" system, known as Cloe PK®.

10/10/05 - Directorate Changes

Cyprotex PLC, the provider of pharmacokinetic technology and information, is pleased to announce the following two board changes to support the Group's future development.

17/08/05 - Interim results for the six months to 30 June 2005

Cyprotex PLC, the drug discovery technology and information company, today reports its interim results for the half year ended 30 June 2005.

17/08/05 - Appointment of Chief Scientific Officer

Cyprotex PLC, the drug discovery technology and information company, is pleased to announce the appointment of Dr Darwin Cheney as Chief Scientific Officer of the Company with immediate effect.

17/08/05 - Cyprotex enters significant long-term contract with Sepracor

Cyprotex PLC, the drug discovery technology and information company, is pleased to announce that it has entered into a significant long-term contract for Cyprotex's integrated Cloe offering with the major US-based pharmaceutical company, Sepracor Inc

10/08/05 - Interim Results - Wednesday 17 August 2005

Cyprotex PLC, the provider of pharmacokinetic technology and information, will be announcing its Interim Results for the 6 months ended 30 June 2005 on Wednesday, 17 August 2005.

01/06/05 - AGM Announcemnt

Cyprotex today announces the outcome of its Annual General Meeting

05/04/05 - Cyprotex Launches Innovative New Screening Service

Cyprotex today announces the launch of its new innovative screening service, Cloe Screen® HERG Safety, for the early and rapid assessment of cardiovascular toxicity.

30/03/05 - Annual Report and Accounts for year ended 31 December 2004

Cyprotex PLC, a drug discovery technology and information company, today publishes its Annual Report and Accounts for the year ended 31 December 2004.

09/03/05 - Preliminary Results for year ended 31 December 2004

Cyprotex PLC, a drug discovery technology and information company, today reports its preliminary results for the year ended 31 December 2004.

24/02/05 - Preliminary Results - Wednesday 9 March 2005

Cyprotex Plc will be announcing its Preliminary Results for the year ended 31 December 2004 on Wednesday 9 March 2005.

21/12/04 - Director Shareholding

Notification of interests of directors and connected persons.

06/12/04 - Director Shareholding

Notification of interests of directors and connected persons.

19/11/04 - Advisor Appointment

Appointment of new advisor.

12/10/04 - Director Shareholding

Notification of interests of directors and connected persons.

08/10/04 - Serono to utilise Cloe Screen™ and Cloe PK™

Cyprotex today announces it has entered into a year-long agreement to provide drug discovery support using its experimental service, Cloe Screen® and its computational prediction technology, Cloe PK® to Europe's leading biotechnology company, Serono.

20/09/04 - Interim Report and Accounts

Cyprotex PLC, a drug discovery and technology and information company, today reports its interim restults for the six months ended 30 June 2004.

09/08/04 - Holding(s) in Company

The Company received notification on 29 July 2004 that, pursuant to the placing announced on 16 January 2004, Artemis Investment Management Limited holds 7,250,000 shares in the Company equating to 5.6947% of the issued share capital.

01/07/04 - Collaboration with Peakdale

Cyprotex and Peakdale Collaborate in ADME Prediction Technology for More Efficient Drug Discovery.

20/04/04 - Directorate change

Cyprotex PLC announces today that David Evans has been appointed to the Board of Directors with immediate effect.

19/04/04 - Preliminary results for 12 month period ended 31 December 2003

Cyprotex PLC, a drug discovery technology and information company, today reports its preliminary results for the year ended 31 December 2003.

19/02/04 - Additional Listing

The Company announces that 1,024,138 new Ordinary Shares of 0.1p each (the 'New Ordinary Shares') have been issued and allotted following an exercise of employee share options.

19/02/04 - Solvay selects Cloe Screen™ for early drug discovery support

Cyprotex (LSE: CRX) today announces it has entered into a new agreement with the pharmaceutical division of Belgian-based Solvay, the international chemicals and pharmaceuticals group, to provide drug discovery support using its Cloe Screen™ technology.

09/02/04 - Additional Listing

The Company announces that 799,200 new Ordinary Shares of 0.1p each (the 'New Ordinary Shares') have been issued and allotted to employees following an exercise of share options.

29/01/04 - Three-year agreement with Roche

Cyprotex (LSE: CRX) today announces a three-year agreement with Roche to provide services in support of Roche's drug discovery unit based in Basel, Switzerland.

22/01/04 - Cyprotex provides support to drug discovery projects at AstraZeneca

Cyprotex (LSE: CRX) today announces a new agreement with AstraZeneca to provide essential information on compounds from their drug discovery projects.

22/01/04 - Directorate changes

Cyprotex plc announces today that Martial Lacroix, Ph.D. has been appointed to the Board of Directors with immediate effect.

21/01/04 - ALTANA Pharma selects Cyprotex for drug discovery support

Cyprotex today announces an agreement with ALTANA Pharma AG to provide drug discovery support using its Cloe Screen™ technology.

16/01/04 - Result of EGM

Cyprotex is pleased to announce that following the announcement made on 23 December 2003 relating to the proposed placing of new shares, at the Extraordinary General Meeting held earlier today, all resolutions were duly passed by members of the Company.

05/01/04 - EGM - Correction of Date

Further to the announcement made by Cyprotex PLC on Wednesday 23 December 2003, the Company would like to make a correction to the EGM date that was stated in the press release. The date for the EGM is Friday 16 January 2004, as set out in the Circular posted to Shareholders, rather than the date of Wednesday 14 January 2004 stated in the original press release.

23/12/03 - Proposed Placing

Cyprotex PLC today announces a proposed placing of 30,000,000 New Ordinary Shares representing 24 per cent. of the enlarged issued ordinary share capital of the Company, at a price of 10p per share to raise £3.0 million gross (approximately £ 2.94 million net of expenses).

16/12/03 - Issue of Equity

Cyprotex PLC has placed 4,500,000 new ordinary shares of 0.1p at a price of 18p per share, to raise £810,000 before expenses. The New Shares represent 4.74% of the enlarged share capital of the Company. Application will be made to AIM for admission of the New Shares to trading, with dealings expected to commence on 19 December.

11/11/03 - Cyprotex reports successful customer validation studies for Cloe™ Technology

Cyprotex (LSE: CRX) today announces results of successful trials of its Cloe PK™ software applied to over 150 potential drugs provided by seven pharmaceutical companies.

30/09/03 - Interim Results for the six months ended 30 June 2003

Cyprotex PLC, a drug discovery and technology information company, today reports its Interim Results for the six month period ended 30 June 2003.

12/08/03 - Appointment of Chairman and Chief Executive

The board of Cyprotex plc are pleased to announce the appointment of Robert Morrisson Atwater as Chairman and Chief Executive of the Company with immediate effect.

12/08/03 - Holding(s) in Company

Pursuant to Schedule 5 of the AIM Rules, regarding the notification of major interests in shares, Cyprotex announces that on 11 August 2003 Nordan Holdings Limited ('Nordan'), an investment vehicle controlled by Aubach Capital Partners Limited ('Aubach'), acquired 29.9% of the Company's Ordinary Share Capital, which was previously held by Mr Paul Davidson.

07/07/03 - Launch of Cloe Screen

Cyprotex today announces their successful completion of the development of a core set of high throughput assay platforms for assessing key properties that determine whether a compound will reside in the body long enough to be effective as a drug.

07/07/03 - Statement re: FSA

Cyprotex plc confirms that the Financial Services Authority (FSA) has discontinued its investigation into the Company and does not have any present intention to take further action in relation to Cyprotex.

07/07/03 - Director Shareholding

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONNEL

23/06/03 - Holding(s) in company

Cyprotex plc received notification on 20 June 2003 from Angus Monro advising that he had disposed of his interests in a certain number of ordinary shares of 0.1p each in the capital of the Company.

13/06/03 - Cyprotex launches Cloe PK™, "virtual human" software to support drug discovery

Cyprotex plc today unveils Cloe PK™, a novel and proprietary software system that accurately predicts, via its "virtual human" model, the pharmacokinetics (PK) of potential drug compounds.

29/05/03 - Cyprotex commences drug development relationship with Avidex

Cyprotex today announces that it has entered into a preclinical agreement with Avidex, the Oxford-based company that develops products for cancer and autoimmunity.

23/05/03 - Appointment of Adviser

The Board of Cyprotex PLC is delighted to announce the appointment of Durlacher Limited as Nominated Adviser and Broker to the Company.

22/05/03 - Closure of Spread Bet

Cyprotex PLC has received today a letter from City Index Limited confirming that all spread bets placed by Paul Davidson with City Index Limited in relation to Cyprotex plc have been unconditionally closed.

15/05/03 - Cancellation of Options

On the 13 May 2003, the Chief Operating Officer, Mr John Nicholson, waived his entitlement to an option to acquire 2,048,276 ordinary shares

01/04/03 - Preliminary results for 14 month period ended 31 December 2002

Cyprotex PLC, a drug discovery technology and information company, today reports its preliminary results for the 14 months to 31 December 2002.

25/03/03 - Board restructuring

Cyprotex plc announced on 17th February 2003 that Dr Mark Egerton, Chief Executive Officer, had declared his intention to step down as CEO.

06/03/03 - Outcome of court action

Cyprotex PLC (LSE: CRX) today announces that in its litigation with the University of Sheffield over disputed software.

20/02/03 - AstraZeneca selects Cyprotex for drug discovery support

Cyprotex (LSE: CRX) today announces that it has entered into an agreement with AstraZeneca AB (LSE:AZN) to provide drug discovery support.

17/02/03 - Board Changes

Cyprotex plc announced today that Dr Colin Picton will become non-executive Chairman of the Company with immediate effect, following the resignation of Jeremy Scudamore.

26/07/02 - Interim Results for the eight months ended 30 June 2002

Cyprotex PLC, a drug discovery technology and information company, today reports its maiden interim results for the eight months to 30 June 2002.

19/07/02 - Interim Results - Friday 26 July 2002

Cyprotex plc, a drug discovery technology and information company, will be announcing its maiden set of Interim Results for the eight months ended 30 June 2002 on Friday 26 July 2002

10/07/02 - Roche selects Cyprotex for drug discovery support

The Cyprotex group (LSE: CRX) today announces that it has entered into an agreement with Roche to provide drug discovery support.

01/05/02 - Appointment of Chief Executive Officer and change in accounting reference date

The board of Cyprotex plc ("Cyprotex" or "the Company") are pleased to announce the appointment of Dr. Mark Egerton as Chief Executive Officer of the Company with immediate effect.

11/04/02 - Cyprotex plc : Resignation of Director

Robert Long has today resigned as a non-executive director of Cyprotex plc with immediate effect.

19/03/02 - Announcement regarding press comment

Further to today's article in the Financial Times the board of Cyprotex would like to confirm that, as published in its prospectus dated 12 February 2002...

07/03/02 - Cyprotex PLC announces contract win with Astex Technology and opening of US facility

Cyprotex PLC ("Cyprotex" or "the Company"), an operator in the predictive data market for drug discovery using advanced lead optimisation techniques...

12/02/02 - Cyprotex PLC publishes full prospectus for AIM admission

Cyprotex PLC, ("Cyprotex" or "the Company"), an operator in the predictive data market for drug discovery using advanced lead optimisation techniques...

03/01/02 - Cyprotex plc announces intention to float on AIM and appointment of Jeremy Scudamore as non-executive Chairman

Cyprotex plc, an operator in the predictive data market for drug discovery using advanced industrial scale testing, today announced its intention to seek admission of its shares to trading on the Alternative Investment Market (AIM).